Edatrexate
Edatrexate Basic information
- Product Name:
- Edatrexate
- Synonyms:
-
- (S)-2-[4-[1-[(2,4-Diaminopteridine-6-yl)methyl]propyl]benzoylamino]pentanedioic acid
- 10-Ethyl-10-deazaaminopterin
- 10-Ethyl-10-deazaaminopterine
- EDX
- N-[4-[1-[(2,4-Diaminopteridin-6-yl)methyl]propyl]benzoyl]-L-glutamic acid
- CGP 30694
- NSC 626715
- FSIRXIHZBIXHKT-MHTVFEQDSA-N
- CAS:
- 80576-83-6
- MF:
- C22H25N7O5
- MW:
- 467.48
- Mol File:
- 80576-83-6.mol
More
Less
Edatrexate Chemical Properties
- Density
- 1.441±0.06 g/cm3(Predicted)
- pka
- 3.56±0.10(Predicted)
More
Less
Edatrexate Usage And Synthesis
Uses
Antineoplastic.
Definition
ChEBI: Edatrexate is a glutamic acid derivative.
in vivo
Edatrexate (0.14 g/kg and 0.21 g/kg; i.p.; twice weekly×3 or weekly×3) exerts potent efficacy against advanced metastatic disease in tumor-bearing mice, better than MTX[1].
| Animal Model: | Murine models of advanced metastatic disease (including E0771 mammary adenocarcinoma, T241 fibrosarcoma, Lewis lung carcinoma, B16 melanoma, or C38 colon carcinoma)[2] |
| Dosage: | 0.14 g/kg and 0.21 g/kg |
| Administration: | Intraperitoneal injection; 0.14 g/kg twice weekly for 3 weeks and 0.21 g/kg weekly for 3 weeks; added Ca leucovorin (LCV) 16, 20, 24 h after Edatrexate treatment |
| Result: | Increased survival of tumor-bearing mice. Showed markedly therapeutic effectiveness against advanced metastatic disease in high-dose regimen with delayed LCV rescue. |
EdatrexateSupplier
LGM Pharma
- Tel
- 1-(800)-881-8210
- inquiries@lgmpharma.com
SIMAGCHEM CORP
- Tel
- +86-13806087780
- sale@simagchem.com
CONIER CHEM AND PHARMA LIMITED
- Tel
- +8618523575427
- sales@conier.com
TargetMol Chemicals Inc.
- Tel
- 15002134094
- marketing@targetmol.cn
TargetMol Chemicals Inc.
- Tel
- +8613564774135
- zijue.cai@tsbiochem.com